Suven Life Sciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine (SUVN-502) for the Treatment of Agitation in Patients with Dementia of the Alzheime